Literature DB >> 29207001

The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.

Natalia Stella-Ascariz1, José Ramón Arribas2, Roger Paredes3, Jonathan Z Li4.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) drug resistance genotyping is recommended to help in the selection of antiretroviral therapy and to prevent virologic failure. There are several ultrasensitive assays able to detect HIV-1 drug-resistance minority variants (DRMVs) not detectable by standard population sequencing-based HIV genotyping assays. Presence of these DRMVs has been shown to be clinically relevant, but its impact does not appear to be uniform across drug classes. In this review, we summarize key evidence for the clinical impact of DRMVs across drug classes for both antiretroviral treatment-naive and antiretroviral treatment-experienced patients, and highlight areas where more supporting evidence is needed.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV-1 drug resistance; drug resistant minority variants; treatment failure

Mesh：

Substances：

Year:  2017        PMID： 29207001      PMCID： PMC5853963          DOI： 10.1093/infdis/jix430

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  50 in total

1.  Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.

Authors:  Sofiane Mohamed; Guillaume Penaranda; Dimitri Gonzalez; Claire Camus; Hacène Khiri; Ronan Boulmé; Chalom Sayada; Patrick Philibert; Daniel Olive; Philippe Halfon
Journal:  AIDS       Date:  2014-06-01       Impact factor: 4.177

2.  Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.

Authors:  Valerie F Boltz; Yu Zheng; Shahin Lockman; Feiyu Hong; Elias K Halvas; James McIntyre; Judith S Currier; Margret C Chibowa; Cecelia Kanyama; Apsara Nair; Willis Owino-Ong'or; Michael Hughes; John M Coffin; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

3.  Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.

Authors:  Charlotte Charpentier; Guinevere Q Lee; Christophe Rodriguez; Benoit Visseaux; Alexandre Storto; Catherine Fagard; Jean-Michel Molina; Christine Katlama; Yazdan Yazdanpanah; P Richard Harrigan; Diane Descamps
Journal:  J Antimicrob Chemother       Date:  2015-03-08       Impact factor: 5.790

4.  Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.

Authors:  Jia Liu; Michael D Miller; Robert M Danovich; Nathan Vandergrift; Fangping Cai; Charles B Hicks; Daria J Hazuda; Feng Gao
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

Review 5.  Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

Authors:  Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Michael J Kozal; Katherine H Hullsiek; Michael D Miller; David R Bangsberg; Daniel R Kuritzkes
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

6.  Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.

Authors:  Martin R Jakobsen; Martin Tolstrup; Ole S Søgaard; Louise B Jørgensen; Paul R Gorry; Alex Laursen; Lars Ostergaard
Journal:  Clin Infect Dis       Date:  2010-02-15       Impact factor: 9.079

7.  Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.

Authors:  Maria Casadellà; Marc Noguera-Julian; Henry Sunpath; Michelle Gordon; Cristina Rodriguez; Mariona Parera; Daniel R Kuritzkes; Vincent C Marconi; Roger Paredes
Journal:  AIDS       Date:  2016-04-24       Impact factor: 4.177

8.  Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.

Authors:  Alessandro Cozzi-Lepri; Marc Noguera-Julian; Francesca Di Giallonardo; Rob Schuurman; Martin Däumer; Sue Aitken; Francesca Ceccherini-Silberstein; Antonella D'Arminio Monforte; Anna Maria Geretti; Clare L Booth; Rolf Kaiser; Claudia Michalik; Klaus Jansen; Bernard Masquelier; Pantxika Bellecave; Roger D Kouyos; Erika Castro; Hansjakob Furrer; Anna Schultze; Huldrych F Günthard; Francoise Brun-Vezinet; Roger Paredes; Karin J Metzner
Journal:  J Antimicrob Chemother       Date:  2014-10-21       Impact factor: 5.790

9.  Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Authors:  Soo-Yon Rhee; Jose Luis Blanco; Michael R Jordan; Jonathan Taylor; Philippe Lemey; Vici Varghese; Raph L Hamers; Silvia Bertagnolio; Tobias F Rinke de Wit; Avelin F Aghokeng; Jan Albert; Radko Avi; Santiago Avila-Rios; Pascal O Bessong; James I Brooks; Charles A B Boucher; Zabrina L Brumme; Michael P Busch; Hermann Bussmann; Marie-Laure Chaix; Bum Sik Chin; Toni T D'Aquin; Cillian F De Gascun; Anne Derache; Diane Descamps; Alaka K Deshpande; Cyrille F Djoko; Susan H Eshleman; Herve Fleury; Pierre Frange; Seiichiro Fujisaki; P Richard Harrigan; Junko Hattori; Africa Holguin; Gillian M Hunt; Hiroshi Ichimura; Pontiano Kaleebu; David Katzenstein; Sasisopin Kiertiburanakul; Jerome H Kim; Sung Soon Kim; Yanpeng Li; Irja Lutsar; Lynn Morris; Nicaise Ndembi; Kee Peng Ng; Ramesh S Paranjape; Martine Peeters; Mario Poljak; Matt A Price; Manon L Ragonnet-Cronin; Gustavo Reyes-Terán; Morgane Rolland; Sunee Sirivichayakul; Davey M Smith; Marcelo A Soares; Vincent V Soriano; Deogratius Ssemwanga; Maja Stanojevic; Mariane A Stefani; Wataru Sugiura; Somnuek Sungkanuparph; Amilcar Tanuri; Kok Keng Tee; Hong-Ha M Truong; David A M C van de Vijver; Nicole Vidal; Chunfu Yang; Rongge Yang; Gonzalo Yebra; John P A Ioannidis; Anne-Mieke Vandamme; Robert W Shafer
Journal:  PLoS Med       Date:  2015-04-07       Impact factor: 11.069

10.  Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.

Authors:  Richard M Gibson; Ashley M Meyer; Dane Winner; John Archer; Felix Feyertag; Ezequiel Ruiz-Mateos; Manuel Leal; David L Robertson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191
View more
  19 in total

1.  Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load.

Authors:  Jessica M Fogel; David Bonsall; Vanessa Cummings; Rory Bowden; Tanya Golubchik; Mariateresa de Cesare; Ethan A Wilson; Theresa Gamble; Carlos Del Rio; D Scott Batey; Kenneth H Mayer; Jason E Farley; James P Hughes; Robert H Remien; Chris Beyrer; Christophe Fraser; Susan H Eshleman
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

2.  Comparison of an In Vitro Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing.

Authors:  Philip L Tzou; Pramila Ariyaratne; Vici Varghese; Charlie Lee; Elian Rakhmanaliev; Carolin Villy; Meiqi Yee; Kevin Tan; Gerd Michel; Benjamin A Pinsky; Robert W Shafer
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

3.  Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data.

Authors:  Kathy K Byrd; John G Hou; Ron Hazen; Heather Kirkham; Sumihiro Suzuki; Patrick G Clay; Tim Bush; Nasima M Camp; Paul J Weidle; Ambrose Delpino
Journal:  J Acquir Immune Defic Syndr       Date:  2019-11-01       Impact factor: 3.731

4.  HIV-1 Drug Resistance Assay Using Ion Torrent Next Generation Sequencing and On-Instrument End-to-End Analysis Software.

Authors:  Michael T Pyne; Keith E Simmon; Melanie A Mallory; Weston C Hymas; Jeffery Stevenson; Adam P Barker; David R Hillyard
Journal:  J Clin Microbiol       Date:  2022-06-14       Impact factor: 11.677

5.  Drug Resistance Mutation Frequency of Single-Genome Amplification-Derived HIV-1 Polymerase Genomes in the Cerebrospinal Fluid and Plasma of HIV-1-Infected Individuals under Nonsuppressive Therapy.

Authors:  Leslie St Bernard; Jeremy Abolade; Hiroshi Mohri; Martin Markowitz; Teresa H Evering
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

6.  Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing.

Authors:  Jenna Weber; Ilona Volkova; Malaya K Sahoo; Philip L Tzou; Robert W Shafer; Benjamin A Pinsky
Journal:  J Mol Diagn       Date:  2019-08-02       Impact factor: 5.568

7.  Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.

Authors:  Jennifer A Fulcher; Yushen Du; Tian-Hao Zhang; Ren Sun; Raphael J Landovitz
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

8.  Microdrop Human Immunodeficiency Virus Sequencing for Incidence and Drug Resistance Surveillance.

Authors:  Sung Yong Park; Gina Faraci; Gary Murphy; Christopher Pilcher; Michael P Busch; Ha Youn Lee
Journal:  J Infect Dis       Date:  2021-09-17       Impact factor: 5.226

9.  Prenylated phloroglucinols from Hypericum scruglii, an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors effective on HIV-1 replication.

Authors:  Cinzia Sanna; Monica Scognamiglio; Antonio Fiorentino; Angela Corona; Vittoria Graziani; Alessia Caredda; Pierluigi Cortis; Mariofilippo Montisci; Elisa Rita Ceresola; Filippo Canducci; Ferruccio Poli; Enzo Tramontano; Francesca Esposito
Journal:  PLoS One       Date:  2018-03-30       Impact factor: 3.240

10.  Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing.

Authors:  Marc Noguera-Julian; Emma R Lee; Robert W Shafer; Rami Kantor; Hezhao Ji
Journal:  Viruses       Date:  2020-06-20       Impact factor: 5.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.